Rivus Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.rivuspharma.com
Clinical Trials
9
Active:1
Completed:7
Trial Phases
2 Phases
Phase 1:5
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (55.6%)Phase 2
4 (44.4%)Relative Bioavailability Study of HU6
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: HU6 150 mg Capsules x 3 (Total dose = 450 mg)Drug: HU6 450 mg Tablet
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Rivus Pharmaceuticals, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT06486558
- Locations
- 🇺🇸
Nucleus Network, Saint Paul, Minnesota, United States
A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Rivus Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06325930
- Locations
- 🇺🇸
Pharmaron Clinical Pharmacology Center (CPC), Baltimore, Maryland, United States
Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Rivus Pharmaceuticals, Inc.
- Registration Number
- NCT06104358
- Locations
- 🇺🇸
AdventHealth Translational Research Institute, Orlando, Florida, United States
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
Phase 2
Active, not recruiting
- Conditions
- Fatty LiverNon-Alcoholic Fatty Liver DiseaseNonalcoholic Steatohepatitis
- Interventions
- Other: Placebo
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Rivus Pharmaceuticals, Inc.
- Target Recruit Count
- 219
- Registration Number
- NCT05979779
- Locations
- 🇺🇸
ProSciento CRU, Chula Vista, California, United States
🇺🇸Velocity Clinical Research, Los Angeles, California, United States
🇺🇸Catalina Research Institute, Montclair, California, United States
Safety and Pharmacokinetics of HU6
Phase 1
Completed
- Conditions
- Obese
- Interventions
- Drug: HU6 TabletDrug: HU6 Capsule
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Rivus Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05433506
- Locations
- 🇺🇸
Nucleus Network, Minneapolis, Minnesota, United States
- Prev
- 1
- 2
- Next
News
No news found